Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency

被引:32
|
作者
Hsu, Chia-Yang [3 ]
Huang, Yi-Hsiang [4 ]
Su, Chien-Wei [5 ]
Chiang, Jen-Huey [2 ,5 ]
Lin, Han-Chieh [5 ]
Lee, Pui-Ching
Lee, Fa-Yauh [5 ]
Huo, Teh-Ia [1 ,6 ]
Lee, Shou-Dong [5 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei 112, Taiwan
[2] Taipei Vet Gen Hosp, Dept Radiol, Taipei 112, Taiwan
[3] Natl Yang Ming Univ Hosp, Dept Med, Yilan, Taiwan
[4] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan
[5] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan
[6] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan
关键词
contrast medium-induced nephropathy; hepatocellular carcinoma; liver cirrhosis; renal insufficiency; transarterial chemoembolization; RISK-FACTORS; INDUCED NEPHROPATHY; STAGING SYSTEMS; CLINICAL-COURSE; FAILURE; DISEASE; MODEL; CIRRHOSIS; STRATEGIES; DIAGNOSIS;
D O I
10.1097/MCG.0b013e3181c88235
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Renal dysfunction is often present in patients with cirrhosis and hepatocellular carcinoma (HCC). Acute renal failure (ARF) may occur after transarterial chemoembolization (TACE) owing to radiocontrast agent. This study investigated the incidence and risk factors of ARF and prognostic predictors in HCC patients with preexisting renal insufficiency undergoing TACE. Methods: A total of 566 HCC patients undergoing TACE were enrolled. Renal insufficiency was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73m(2). Results: In a mean follow-up duration of 18 +/- 16 months, 231 (40.8%) patients undergoing TACE died. Renal insufficiency that was present in 134 (23.7%) patients at baseline, independently predicted a poor prognosis in the Cox proportional hazards model [risk ratio (RR): 1.47, P = 0.012]. Of them, 13 (10%) and 6 (5%) patients had transient and prolonged ARF after TACE, respectively. Post-TACE gastrointestinal bleeding [odds ratio (OR): 16.54, P = 0.001] and higher Cancer of the Liver Italian Program (CLIP) scores (>= 2; OR: 4.22, P = 0.02) were independent risk factors for ARF in the multivariate logistic regression analysis. In the Cox model, prolonged ARF (RR: 3.28, P < 0.001) and higher CLIP scores (>= 2; RR: 2.13, P < 0.001) were independent poor prognostic predictors for HCC patients with renal insufficiency receiving TACE. Conclusions: Gastrointestinal bleeding and higher CLIP scores are associated with the development of ARF in patients with HCC and renal insufficiency undergoing TACE. Higher CLIP scores and renal insufficiency, either preexisting before TACE or as a complication of TACE, are poor prognostic predictors in HCC patients receiving TACE.
引用
收藏
页码:E171 / E177
页数:7
相关论文
共 50 条
  • [21] Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma
    Xu, Xiaojing
    Huang, Peixin
    Tian, Hui
    Chen, Yi
    Ge, Ningling
    Tang, Wengquing
    Yang, Biwei
    Xia, Jinglin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (06) : 1273 - 1278
  • [22] Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma
    Tan, Bin-Bin
    Fu, Ying
    Shao, Ming-Hua
    Chen, Hai-Lei
    Liu, Ping
    Fan, Chao
    Zhang, Hui
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (09):
  • [23] Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    Zhao, Dongxu
    Xu, Wei
    Zhan, Yi
    Xu, Lin
    Ding, Wenbin
    Xu, Aibing
    Hou, Zhongheng
    Ni, Caifang
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [24] Sunitinib versus sorafenib plus transarterial chemoembolization for inoperable hepatocellular carcinoma patients
    Xu, Qiang
    Huang, Youhua
    Shi, Hongjian
    Song, Qian
    Xu, Yuanfeng
    JOURNAL OF BUON, 2018, 23 (01): : 193 - 199
  • [25] The Outcomes of Elderly Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization
    Yau, Thomas
    Yao, Tzy Jyun
    Chan, Pierre
    Epstein, Richard John
    Ng, Kelvin K.
    Chok, Siu Ho
    Cheung, Tan Teo
    Fan, Sheung Tat
    Poon, Ronnie Tung Ping
    CANCER, 2009, 115 (23) : 5507 - 5515
  • [26] Sorafenib combined with transarterial chemoembolization prolongs survival of patients with advanced hepatocellular carcinoma
    Liu, Quanguo
    Dai, Yajie
    JOURNAL OF BUON, 2020, 25 (02): : 945 - 951
  • [27] Transarterial chemoembolization and bland embolization for hepatocellular carcinoma
    Emmanuel A Tsochatzis
    Evangelia Fatourou
    James O'Beirne
    Tim Meyer
    Andrew K Burroughs
    World Journal of Gastroenterology, 2014, 20 (12) : 3069 - 3077
  • [28] Transarterial chemoembolization for hepatocellular carcinoma - New developments
    Kuhl C.
    Der Gastroenterologe, 2009, 4 (4): : 330 - 339
  • [29] Transarterial chemoembolization for hepatocellular carcinoma - new developments
    Kuhl, C.
    GASTROENTEROLOGE, 2009, 4 (04): : 330 - 339
  • [30] Transarterial Chemoembolization Treatment Paradigms for Hepatocellular Carcinoma
    Fite, Elliott L.
    Makary, Mina S.
    CANCERS, 2024, 16 (13)